Mini-Review
The emerging role of chemokine receptor CXCR2 in cancer progression
Translational Cancer Research
2016;
5
(Suppl 4)
:S616-S628
.
(31 October 2016)
Editorial
Liquid biopsy in non-small cell lung cancer: come of age
Translational Cancer Research
2016;
5
(Suppl 4)
:S629-S631
.
(31 October 2016)
The “liquid biopsy” in non-small cell lung cancer—not quite ready for prime time use
Translational Cancer Research
2016;
5
(Suppl 4)
:S632-S635
.
(31 October 2016)
Commentary on “A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors”
Translational Cancer Research
2016;
5
(Suppl 4)
:S636-S639
.
(31 October 2016)
Is it useful to combine taxanes with targeted agents in mCRPC patients—have we hit the target in this phase II study with docetaxel and curcumin allowing going for a phase III study?
Translational Cancer Research
2016;
5
(Suppl 4)
:S640-S644
.
(31 October 2016)
Pathogenesis of acute gastroesophageal reflux disease might be changing
Translational Cancer Research
2016;
5
(Suppl 4)
:S645-S647
.
(31 October 2016)
Defining differential roles for microglia and infiltrating macrophages in the growth and neovascularization of glioma
Translational Cancer Research
2016;
5
(Suppl 4)
:S648-S651
.
(31 October 2016)
Immune infiltration, glioma stratification, and therapeutic implications
Translational Cancer Research
2016;
5
(Suppl 4)
:S652-S656
.
(31 October 2016)
Can combination chemotherapy be standard therapy for sensitive relapsed small-cell-lung cancer?
Translational Cancer Research
2016;
5
(Suppl 4)
:S657-S658
.
(31 October 2016)
Chemotherapy plus intercalated or continuous EGFR-TKI in advanced non-small cell lung cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S659-S663
.
(31 October 2016)
miRNA based signature for predicting epithelial ovarian cancer relapse-progression: a step forward to prime time clinical adoption?
Translational Cancer Research
2016;
5
(Suppl 4)
:S664-S667
.
(31 October 2016)
Immune checkpoint regulator: a new assignment proposed for the classic adhesion molecule P-selectin glycoprotein ligand-1
Translational Cancer Research
2016;
5
(Suppl 4)
:S668-S671
.
(31 October 2016)
Tregs, Helios and tumor immunity: the sun has not yet risen
Translational Cancer Research
2016;
5
(Suppl 4)
:S672-S674
.
(31 October 2016)
Pancreatic cancer immunotherapy: coming of age
Translational Cancer Research
2016;
5
(Suppl 4)
:S675-S679
.
(31 October 2016)
Glioblastoma: does PET shed light to a difficult problem?
Translational Cancer Research
2016;
5
(Suppl 4)
:S680-S683
.
(31 October 2016)
Hypofractionation for postoperative breast cancer radiotherapy: is acute toxicity a limiting factor?
Translational Cancer Research
2016;
5
(Suppl 4)
:S684-S687
.
(31 October 2016)
Hypofractionated radiotherapy for breast cancer: too fast or too much?
Translational Cancer Research
2016;
5
(Suppl 4)
:S688-S693
.
(31 October 2016)
The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better
Translational Cancer Research
2016;
5
(Suppl 4)
:S694-S696
.
(31 October 2016)
Pancreatic cancer-derived exosomes: new role in paraneoplastic syndromes?
Translational Cancer Research
2016;
5
(Suppl 4)
:S697-S700
.
(31 October 2016)
What is the role of stereotactic body radiotherapy to treat inoperable hepatocellular carcinoma?
Translational Cancer Research
2016;
5
(Suppl 4)
:S701-S702
.
(31 October 2016)
Radiofrequency ablation and stereotactic body radiotherapy as non-surgical options for hepatocellular carcinoma
Translational Cancer Research
2016;
5
(Suppl 4)
:S703-S707
.
(31 October 2016)
The potential of proteogenomics in oncology
Translational Cancer Research
2016;
5
(Suppl 4)
:S708-S712
.
(31 October 2016)
Beyond genomics: biologic insights from the CPTAC proteogenomic analysis of breast cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S713-S715
.
(31 October 2016)
Intravenous and intraperitoneal paclitaxel with S-1: new hope for patients with pancreatic cancer and peritoneal metastases?
Translational Cancer Research
2016;
5
(Suppl 4)
:S716-S721
.
(31 October 2016)
Deciphering ZIC2/OCT4 signaling as a vulnerability in liver cancer stem cells
Translational Cancer Research
2016;
5
(Suppl 4)
:S722-S724
.
(31 October 2016)
Autophagy is required for PTEN-loss driven prostate cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S725-S729
.
(31 October 2016)
Targeting pancreatic stellate cells to improve pancreatic cancer radiosensitivity
Translational Cancer Research
2016;
5
(Suppl 4)
:S730-S737
.
(31 October 2016)
Resistance mechanisms in glioblastoma stem cells: finding opportunities in challenges
Translational Cancer Research
2016;
5
(Suppl 4)
:S738-S741
.
(31 October 2016)
Shuttling towards a predictive assay for radiotherapy
Translational Cancer Research
2016;
5
(Suppl 4)
:S742-S746
.
(31 October 2016)
Macrohistone H2A1 takes the center stage in cancer research as a regulator of stemness
Translational Cancer Research
2016;
5
(Suppl 4)
:S747-S750
.
(31 October 2016)
Emerging role for USP1 in glioblastoma stem cell maintenance and radioresistance: a potential target for glioblastoma therapy
Translational Cancer Research
2016;
5
(Suppl 4)
:S751-S754
.
(31 October 2016)
Exosomes containing adrenomedullin mediate new onset diabetes and weight loss in pancreatic cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S755-S757
.
(31 October 2016)
Perspective
Role of the lncRNAs in malignant melanoma and their involvement in metastasis
Translational Cancer Research
2016;
5
(Suppl 4)
:S758-S764
.
(31 October 2016)
Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?
Translational Cancer Research
2016;
5
(Suppl 4)
:S765-S771
.
(31 October 2016)
Perspective on therapeutic application of selective internal radiotherapy in colorectal cancer liver metastasis
Translational Cancer Research
2016;
5
(Suppl 4)
:S772-S777
.
(31 October 2016)
A new fertility risk rating system for surgical, radiotherapy, and chemotherapy interventions used in testicular cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S778-S781
.
(31 October 2016)
Glioblastoma stem cells differentiation through epigenetic modulation is driven by miR-296-5p/HMGA1/Sox2 axis
Translational Cancer Research
2016;
5
(Suppl 4)
:S782-S788
.
(31 October 2016)
PIK3CA mutated, hormonal receptors and HER2: individual targets but partnered in the escape to targeted therapy in breast cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S789-S793
.
(31 October 2016)
Can we stop the progression of chronic liver disease to hepatocellular carcinoma?
Translational Cancer Research
2016;
5
(Suppl 4)
:S794-S799
.
(31 October 2016)
Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer: Clinical perspectives and research opportunities
Translational Cancer Research
2016;
5
(Suppl 4)
:S800-S802
.
(31 October 2016)
Emerging mutations and functional changes of androgen receptor associated with treatment resistance in prostate cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S803-S808
.
(31 October 2016)
New insights into patient radiosensitivity in relation to the biology of the ATM protein
Translational Cancer Research
2016;
5
(Suppl 4)
:S809-S814
.
(31 October 2016)
Is inhibiting the DNA damage response the answer to treatment resistance in glioma stem cells?
Translational Cancer Research
2016;
5
(Suppl 4)
:S815-S822
.
(31 October 2016)
Commentary
Diagnostic performance of [18F] fluorodeoxyglucose PET/CT and diffusion-weighted magnetic resonance imaging for the evaluation of treatment response to induction chemotherapy followed by definitive chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
Translational Cancer Research
2016;
5
(Suppl 4)
:S823-S826
.
(31 October 2016)
Emerging molecular mechanisms underlying cancer metastasis: the rising role of the long non-coding RNA GAS5
Translational Cancer Research
2016;
5
(Suppl 4)
:S827-S830
.
(31 October 2016)
A new angle on Notch combination therapies
Translational Cancer Research
2016;
5
(Suppl 4)
:S831-S835
.
(31 October 2016)
Intracranial activity of crizotinib: something to rely on?
Translational Cancer Research
2016;
5
(Suppl 4)
:S836-S838
.
(31 October 2016)
Selective FcγR engagement by human agonistic anti-CD40 antibodies
Translational Cancer Research
2016;
5
(Suppl 4)
:S839-S841
.
(31 October 2016)
New applications for deep sequencing of the T cell receptor repertoire in cancer patients
Translational Cancer Research
2016;
5
(Suppl 4)
:S842-S843
.
(31 October 2016)
The prospective correlation between GGN and CAG repeat polymorphisms of androgen receptors and testicular cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S844-S846
.
(31 October 2016)
The challenge for precision medicine: all tumor genomes are different and all cancer patients are different in their own way
Translational Cancer Research
2016;
5
(Suppl 4)
:S847-S851
.
(31 October 2016)
In vivo modeling of diffuse large B cell lymphoma (DLBCL) with the myeloid differentiation primary response gene 88 (MYD88) L265P mutationon
Translational Cancer Research
2016;
5
(Suppl 4)
:S852-S854
.
(31 October 2016)
T cells exert force for pMHC pull-ups
Translational Cancer Research
2016;
5
(Suppl 4)
:S855-S857
.
(31 October 2016)
Perspective towards the clinical application of eribulin in soft tissue sarcomas
Translational Cancer Research
2016;
5
(Suppl 4)
:S858-S861
.
(31 October 2016)
Risk stratification in prostate cancer treated with radiation therapy: a window of opportunity for new clinical trials
Translational Cancer Research
2016;
5
(Suppl 4)
:S862-S864
.
(31 October 2016)
Prospecting for prostate cancer with precision medicine
Translational Cancer Research
2016;
5
(Suppl 4)
:S865-S867
.
(31 October 2016)
Novel therapeutic strategies against cancer and chronic infection by targeting P-selectin glycoprotein ligand-1 as an immune T cells response regulator
Translational Cancer Research
2016;
5
(Suppl 4)
:S868-S871
.
(31 October 2016)
The immunogenicity of cancer mutations and implications for T cell therapy
Translational Cancer Research
2016;
5
(Suppl 4)
:S872-S874
.
(31 October 2016)
CIS is a negative regulator of IL-15-mediated signals in NK cells
Translational Cancer Research
2016;
5
(Suppl 4)
:S875-S877
.
(31 October 2016)
An unhealthy diet: making sense of a fatty niche for leukemia stem cells
Translational Cancer Research
2016;
5
(Suppl 4)
:S878-S881
.
(31 October 2016)
Vagus nerve-preserving distal gastrectomy may improve the quality of life after gastrectomy in early stage gastric cancer patients
Translational Cancer Research
2016;
5
(Suppl 4)
:S882-S884
.
(31 October 2016)
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage
Translational Cancer Research
2016;
5
(Suppl 4)
:S885-S888
.
(31 October 2016)
Is there any role for liver resection in the treatment of liver metastases from gastric carcinoma?
Translational Cancer Research
2016;
5
(Suppl 4)
:S889-S891
.
(31 October 2016)
Malignant pleural mesothelioma: beyond the mathematical models
Translational Cancer Research
2016;
5
(Suppl 4)
:S892-S894
.
(31 October 2016)
Phenotype: the result of a complex and still largely unknown interplay between molecules
Translational Cancer Research
2016;
5
(Suppl 4)
:S895-S897
.
(31 October 2016)
S-1: changing the facets of adjuvant chemotherapy in pancreatic cancer?
Translational Cancer Research
2016;
5
(Suppl 4)
:S898-S902
.
(31 October 2016)
Breast cancer following childhood cancer—more to the story than we thought
Translational Cancer Research
2016;
5
(Suppl 4)
:S903-S906
.
(31 October 2016)
Should pertuzumab be used as part of neoadjuvant treatment prior to the release of the APHINITY trial results?
Translational Cancer Research
2016;
5
(Suppl 4)
:S907-S912
.
(31 October 2016)
MicroRNA master regulator of hematopoiesis may also hold the key to B-cell lymphoma pathogenesis and therapy
Translational Cancer Research
2016;
5
(Suppl 4)
:S913-S915
.
(31 October 2016)
Comparison of quantitative faecal immunochemical tests for haemoglobin (FIT) for asymptomatic population screening
Translational Cancer Research
2016;
5
(Suppl 4)
:S916-S919
.
(31 October 2016)
Targeting the ubiquitin proteasome system in glioblastoma
Translational Cancer Research
2016;
5
(Suppl 4)
:S920-S922
.
(31 October 2016)
Radioprotective properties of myeloid-derived suppressor cells
Translational Cancer Research
2016;
5
(Suppl 4)
:S923-S925
.
(31 October 2016)
Correspondence
Targeting long non-coding RNAs (lncRNAs) with oligonucleotides in cancer therapy
Translational Cancer Research
2016;
5
(Suppl 4)
:S926-S927
.
(31 October 2016)
Novel mechanism of immune evasion involving PD-L1 in various cancers
Translational Cancer Research
2016;
5
(Suppl 4)
:S928-S929
.
(31 October 2016)
Challenges and opportunities of CYP3A5 as novel drug target in pancreatic cancer subtypes
Translational Cancer Research
2016;
5
(Suppl 4)
:S930-S931
.
(31 October 2016)
The role of PET CT in the management of advanced nodal head neck cancer post chemoradiotherapy
Translational Cancer Research
2016;
5
(Suppl 4)
:S932
.
(31 October 2016)
Tumor specific theranostic streptavidin-coupled superparamagnetic iron oxide nanoparticles for targeting therapeutic moieties in pancreatic cancer
Translational Cancer Research
2016;
5
(Suppl 4)
:S933-S935
.
(31 October 2016)
Disclosure:
This supplement was published without any sponsorship or funding.
